NuCana PLC
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate anti-cancer metabolites in cancer cells. Its pipeline in… Read more
NuCana PLC (NCNA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.049x
Based on the latest financial reports, NuCana PLC (NCNA) has a cash flow conversion efficiency ratio of 0.049x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.28 Million) by net assets ($25.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NuCana PLC - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how NuCana PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
NuCana PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NuCana PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SYNOPSYS (SYP.SG)
STU:SYP
|
0.059x |
|
TON Strategy Co
NASDAQ:TONX
|
-0.015x |
|
Major Development Public Company Limited
BK:MJD
|
-0.052x |
|
ValiRx plc
LSE:VAL
|
-0.233x |
|
SIAV S.P.A.
F:F4U
|
N/A |
|
KAP AG
F:IUR
|
0.002x |
|
INE0
F:INE0
|
N/A |
|
LFE Corporation Bhd
KLSE:7170
|
-0.194x |
Annual Cash Flow Conversion Efficiency for NuCana PLC (2014–2024)
The table below shows the annual cash flow conversion efficiency of NuCana PLC from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.95 Million | $-19.12 Million | -3.211x | -80.80% |
| 2023-12-31 | $14.89 Million | $-26.44 Million | -1.776x | -195.27% |
| 2022-12-31 | $38.50 Million | $-23.16 Million | -0.601x | -65.49% |
| 2021-12-31 | $65.55 Million | $-23.82 Million | -0.363x | -66.83% |
| 2020-12-31 | $99.23 Million | $-21.62 Million | -0.218x | +41.93% |
| 2019-12-31 | $63.52 Million | $-23.83 Million | -0.375x | -150.44% |
| 2018-12-31 | $81.59 Million | $-12.22 Million | -0.150x | -60.72% |
| 2017-12-31 | $93.42 Million | $-8.71 Million | -0.093x | +74.60% |
| 2016-12-31 | $25.24 Million | $-9.26 Million | -0.367x | -146.16% |
| 2015-12-31 | $29.96 Million | $-4.47 Million | -0.149x | +99.90% |
| 2014-12-31 | $34.51K | $-5.25 Million | -151.998x | -- |